References
- Amadio P Jr. Cummings DM, Amadio PB. Tailoring the antihypertensive drug regimen. Am Fam Physician 1986: 34(2): 157–70 (published errata appear in Am Fam Physician 1987: 35(1): 26; 1987: 35(6): 49)
- Kaplan NM. Adrenergic inhibitors: beta blockers. In: Clinical hypertension. 4th ed. Baltimore: Williams & Wilkins, 1986: 218–30
- Mason DT. Introduction, improved beta adrenergic blockade therapy: results of acebutolol trials. Am Heart J 1985: 109(5 Pt 2): 1119
- Koepke JP, DiBona GF. Managing fatigue in beta-blocker patients. Physician Clin Financial World 1986: 1(1): 1–9
- De Bono G, Kaye CM, Roland E, et al. Acebutolol: ten years of experience. Am Heart J 1985: 109(5 Pt 2): 1211–3
- Abernethy DR, Arendt RM, Greenblatt DJ. Pharmacologic properties of acebutolol: relationship of hydrophilicity to central nervous system penetration. Am Heart J 1985: 109(5 Pt 2): 1120–5
- Singh BN, Thoden WR, Wahl J. Acebutolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects. Pharmacotherapy 1986: 6(2): 45–63
- Singh BN, Thoden WR, Ward A. Acebutolol: a review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia. Drugs 1985: 29(6): 531–69
- Gengo FM, Huntoon L, McHugh WB. Lipid-soluble and water-soluble beta-blockers: comparison of the central nervous system depressant effect. Arch Intern Med 1987: 147(1): 39–43
- Giacomini JC, Thoden WR. Ancillary pharmacologic properties of acebutolol: cardioselectivity, partial agonist activity, and membrane-stabilizing activity. Am Heart J 1985: 109(5 Pt 2): 1137–44
- Benson MK, Berrill WT, Cruickshank JM, et al. A comparison of four beta-adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol 1978: 5(5): 415–9
- Trap-Jensen J, Carlsen JE, Svendsen TL, et al. Cardiovascular and adrenergic effects of cigarette smoking during immediate non-selective and selective beta adrenoceptor blockade in humans. Eur J Clin Invest 1979: 9(3): 181–3
- Tsukiyama H, Otsuka K, Higuma K. Effects of beta-adrenoceptor antagonists on central hemodynamics in essential hypertension. Br J Clin Pharmacol 1982: 13(Suppl 2): 269–78S
- Taylor SH. Intrinsic sympathomimetic activity: clinical fact or fiction? Am J Cardiol 1983: 52(9): 16–26D
- Wahl J, Turlapaty R Singh BN. Comparison of acebutolol and propranolol in essential hypertension. Am Heart J 1985: 109(5 Pt 2): 313–21
- Lund-Johansen P. The role of drugs in countering adverse pathophysiological profiles: influence on hemodynamics. In: Taylor SH, ed. Hypertension as a factor in the coronary risk profile. Abstracts from symposium preceding Xth World Congress of Cardiology. Washington. DC: 1986 Sep 13. p 12
- White WB. Beta-adrenergic blocking agents with intrinsic sympathomimetic activity: clinical pharmacology and therapeutic applications. Physician Clin Financial World 1987: 2(1): 1–9
- Lehtonen A. Effect of beta blockers on blood lipid profile. Am Heart J 1985: 109(5 Pt 2): 1192–6
- Miller NE. Effects of beta-blocking drugs on plasma lipid profile. In: Taylor SH, ed,16 p 19
- Wallin JD, Shah SV. Beta-adrenergic blocking agents in the treatment of hypertension: choices based on pharmacological properties and patient characteristics. Arch Intern Med 1987: 147(4): 654–9
- Messerli FH. Pathophysiologc mechanisms in essential hypertension: a clue to the therapeutic approach. J Cardiovasc Pharmacol 1984: 6(Suppl 6): 875–9S
- Frohlich ED, Messerli FH, Dunn FG, et al. Greater renal vascular involvement in the black patient with essential hypertension: a comparison of systemic and renal hemodynamics in black and white patients. Miner Electrolyte Metab 1984: 10(3): 173–7
- Lund-Johansen P. Central haemodynamic effects of beta blockers in hypertension: a comparison between atenolol, metoprolol, timolol, penbutolol, alprenolol. pindolol, and bunitrolol. Eur Heart J 1983: 4(Suppl D): 1–12
- Boyles PW. Effects of age and race on clinical response to acebutolol in essential hypertension. Am Heart J 1985: 109(5 Pt 2): 1184–92